Exact Sciences Worth Adding to Your Watchlist After Strong Q4 Results

If you’re tracking healthcare stocks for your watchlist, Exact Sciences Corporation’s fourth-quarter 2025 performance warrants attention. The company delivered mixed signals—matching earnings expectations while exceeding revenue forecasts—suggesting it remains a stock worth monitoring.

Revenue Surge Outperforms Market Expectations

Exact Sciences announced consolidated fourth-quarter revenues of $878.4 million, representing a 23.1% year-over-year increase on a reported basis and 23% growth on a core revenue basis. This performance surpassed the Zacks Consensus Estimate by 2.1%, marking a solid top-line achievement. For the full year 2025, consolidated revenues climbed to $3.25 billion, up 17.7% on a reported basis and 18% on a core revenue basis.

Following the earnings release, EXAS shares edged up marginally by 0.07%, suggesting measured investor confidence. While not a dramatic move, the stock’s stability reflects the market’s acknowledgment of solid operational execution.

Business Segments Drive Growth Trajectory

The company’s two core segments contributed meaningfully to revenue growth. The Screening segment—encompassing laboratory services from Cologuard and PreventionGenetics—generated $695.1 million in revenues, increasing 26% year over year. This robust performance highlights strong demand for colorectal and genetic screening services.

The Precision Oncology division, which includes global Oncotype products and therapy selection solutions, posted $183.2 million in revenues. This segment grew 14% year over year and 12% on a core basis, demonstrating steady momentum in the oncology diagnostics space.

Profitability Metrics Show Encouraging Trends

Gross profit expanded to $615.8 million, rising 25% year over year. More importantly, the gross margin widened by 106 basis points to 70.1%, indicating improved operational leverage and better cost management relative to revenues.

However, escalating expenses present a countervailing force. Research and development spending nearly doubled, climbing 96% year over year to $191.5 million. Sales and marketing expenses increased 18% to $288.5 million, while general and administrative costs rose 14.1% to $218 million. Adjusted operating expenses totaled $698 million, up 30.9% year over year, resulting in an adjusted operating loss of $82.2 million compared with $40.8 million in the prior year period.

The bottom-line picture reflected this tension: the company reported a net loss of 21 cents per share in Q4 2025, compared with a 6-cent loss in Q4 2024—matching the Zacks Consensus Estimate. Full-year 2025 earnings per share stood at 7 cents versus a 23-cent loss in 2024, showing improvement on an annual basis despite quarterly losses.

Balance Sheet and Liquidity Assessment

Exact Sciences exited the quarter with $964.7 million in cash and marketable securities, compared with $1.04 billion a year earlier. While cash declined modestly, the company generated $491.4 million from operating activities over the full year 2025, substantially higher than the $210.5 million in the prior year—a positive indicator of cash generation capability.

Strategic Developments Keep Investors Watching

Two significant developments warrant inclusion on any serious watchlist. First, the company announced favorable clinical study results from its Oncodetect molecular residual disease test for breast cancer screening, and separately reported pivotal clinical validation results from the ALTUS study. These advancements reinforce the company’s pipeline strength in oncology diagnostics.

More consequentially, on November 19, 2025, Exact Sciences entered into a merger agreement with Abbott Laboratories and Badger Merger Sub I, Inc. The parties are continuing regulatory engagement with anticipated closing in the second quarter of 2026, pending required approvals. This transformational transaction could reshape the company’s trajectory and is a key monitoring point for investors.

The Investment Perspective: Why Remain on Your Watchlist?

Exact Sciences presents a nuanced investment case. On the positive side, revenue acceleration and margin expansion demonstrate operational momentum and pricing power. The robust Screening segment performance and clinical breakthroughs in oncology diagnostics validate its market positioning. The strong operating cash generation of $491.4 million suggests the business is beginning to fund itself more effectively.

Conversely, mounting expenses and persistent operating losses raise valid caution. The 96% surge in R&D spending, while reflecting growth investments, is outpacing revenue growth and creating financial pressure. The net loss in the quarter, though matching forecasts, underscores the path to profitability remains uncertain.

The pending Abbott merger represents both opportunity and risk—it provides strategic partnering and validation but also introduces regulatory and execution uncertainty given the projected Q2 2026 closing.

For investors monitoring healthcare diagnostics opportunities, Exact Sciences merits continued attention. The combination of strong revenue dynamics, improving margins, and strategic catalyst events suggests the stock could move materially once regulatory clarity emerges on the Abbott transaction. Whether it ultimately belongs in your core portfolio or remains a satellite watchlist position likely depends on your risk tolerance and conviction around the merger’s success.